Join us at the World Conference on Lung Cancer (WCLC) in Barcelona, Spain from September 6-9, 2025. Visit us at Booth #420 to discover the latest advancements in eyonis® LCS: our AI/ML technology-based Software as a Medical Device designed to support radiologists and pulmonologists in lung cancer screening.

Median Technologies submits U.S. application for 510(k) clearance of eyonis® LCS

Median Technologies reports 2025 Q1 key financial indicators and provides an update on Q1 key operational achievements.

RELIVE pivotal study final results show that Median’s eyonis™ LCS SaMD met all key endpoints, demonstrating statistically significant performance, superior to state of the art, as well as device safety and efficacy. The results support the intended use for which eyonis™ LCS was developed, which was shared with the EU Notified Body and discussed with the FDA during the Q-submission phase.

Median will be exhibiting at the ESMO Congress on October 17 – 21 in Berlin. Happy to see you there at Messe Berlin!